|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-11-29
|
|
pubmed:abstractText |
The present study was designed with the aim of evaluating the tolerability and activity of pegylated liposomial doxorubicin (PLD) in combination with weekly docetaxel as first line treatment of advanced breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0167-6806
|
|
pubmed:author |
pubmed-author:CastellanaMaria AngelaMA,
pubmed-author:De SioLiviaL,
pubmed-author:FanelliMassimoM,
pubmed-author:FerraùFrancescoF,
pubmed-author:GaspariniGiampietroG,
pubmed-author:GattusoDomenicoD,
pubmed-author:Lo VulloSalvatoreS,
pubmed-author:LorussoVitoV,
pubmed-author:MarianiLuigiL,
pubmed-author:MorabitoAlessandroA,
pubmed-author:PrioloDomenicoD,
pubmed-author:SarmientoRobertaR,
pubmed-author:StaniSimonetta ChiaraSC,
pubmed-author:VitaleStefanoS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
249-57
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15567941-Adult,
pubmed-meshheading:15567941-Aged,
pubmed-meshheading:15567941-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15567941-Breast Neoplasms,
pubmed-meshheading:15567941-Disease Progression,
pubmed-meshheading:15567941-Doxorubicin,
pubmed-meshheading:15567941-Drug Administration Schedule,
pubmed-meshheading:15567941-Female,
pubmed-meshheading:15567941-Humans,
pubmed-meshheading:15567941-Liposomes,
pubmed-meshheading:15567941-Maximum Tolerated Dose,
pubmed-meshheading:15567941-Middle Aged,
pubmed-meshheading:15567941-Survival Analysis,
pubmed-meshheading:15567941-Taxoids,
pubmed-meshheading:15567941-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
|
|
pubmed:affiliation |
Division of Medical Oncology, San Filippo Neri Hospital, Rome, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
